Skip to main content

Hemp Topicals (CBD Creams, Balms, Salves)

Federal: Legal

External-use hemp-derived products that deliver cannabinoids through the skin to localized areas. Non-intoxicating in standard formulations. Widely used for muscle and joint discomfort. Federally legal under the 2018 Farm Bill; least restricted of the hemp product categories at the state level.

Federal basis

2018 Farm Bill §10113. Topicals contain CBD and minor cannabinoids; standard formulations do not deliver intoxicating doses of THC through the skin.

Common forms

  • Creams and lotions
  • Balms and salves
  • Roll-ons
  • Transdermal patches
  • Massage oils
  • Bath products (bath bombs, soaks)

Common uses

  • Localized muscle and joint discomfort
  • Skin conditions (consumer use; clinical evidence is limited)
  • Post-exercise recovery

Safety notes

  • Standard topicals (creams, balms) do not produce systemic cannabinoid exposure and do not cause intoxication. Transdermal patches are different: they are engineered to deliver cannabinoids through the skin into the bloodstream and can produce psychoactive effects if they contain THC.
  • Topicals containing only CBD typically do not produce positive drug tests. Transdermal THC patches will.
  • Patch test on a small area before broad application. Carrier ingredients (essential oils, menthol, lidocaine in combo products) can cause irritation.
  • Avoid eyes, mucous membranes, and broken skin unless the product is specifically formulated for that use.

Hemp topicals are the least-restricted category of hemp-derived products. They are sold in mainstream retail (pharmacies, sporting goods stores, grocery) in nearly every state and are not typically subject to age restrictions.

Standard topicals vs. transdermal patches

A standard cream, balm, or lotion delivers cannabinoids to local skin and muscle tissue. It does not produce systemic blood levels and does not cause intoxication. A transdermal patch is different: it uses penetration enhancers and time-release formulation to deliver cannabinoids into the bloodstream. THC-containing transdermal patches can produce psychoactive effects and positive drug tests.

What the evidence supports

Clinical evidence for topical CBD is limited but growing for localized inflammatory and musculoskeletal complaints. Evidence for skin conditions like eczema and psoriasis is preliminary. FDA does not recognize any therapeutic claims for over-the-counter hemp topicals.

Sources

  1. FDA: FDA Regulation of Cannabis and Cannabis-Derived Productsaccessed May 17, 2026
  2. Cleveland Clinic: CBD Topicalsaccessed May 17, 2026